Is Yellow Fever Still Around? Cases, Risks & Vaccine

Yellow fever is very much still around. Modeling based on the Global Burden of Disease database estimated roughly 87,000 new cases in 2021, and a separate study pegged the number of severe infections in 2018 at about 109,000, with around 51,000 deaths across Africa and South America in that year alone.¹ The disease circulates continuously in tropical regions of those two continents, and periodic outbreaks remind the world that this centuries-old virus has not been tamed. A safe, effective vaccine exists and remains the single best defense, but gaps in coverage, climate pressures, and the sheer biology of the virus keep yellow fever on the list of global health threats.

Where Yellow Fever Occurs Today

Yellow fever is endemic in 47 countries: 34 in Africa and 13 in the Americas. The highest incidence rates are found in Western, Central, and Eastern sub-Saharan Africa.² In South America, Brazil has been the epicenter of the largest recent outbreaks: between 2016 and 2019, a wave of cases swept through the southeastern states, recording over 1,800 confirmed human cases and nearly 600 deaths in less than 18 months.³ Smaller outbreaks pop up regularly in countries like Nigeria, the Democratic Republic of the Congo, and other parts of West and Central Africa.

The good news is that the overall trend has been downward. Between 1990 and 2021, the number of incident cases dropped by about 75%, and the age-standardized incidence rate fell by nearly 5% per year over that period.² Mass vaccination campaigns in Africa deserve much of the credit: one modeling study estimated these campaigns reduced deaths by about 47%.¹ But “declining” and “gone” are very different things. The virus persists in forest-dwelling mosquitoes and non-human primates, and as long as that wild reservoir exists, human outbreaks remain one unvaccinated community away.

How Yellow Fever Spreads

Yellow fever virus is carried by mosquitoes and maintained in nature through a cycle involving non-human primates. In Africa and South America, the virus circulates among monkeys in forest canopies, passed along by tree-dwelling mosquito species. Humans typically get infected when they venture into or live near forested areas where these mosquitoes bite. This is called the sylvatic (forest) cycle, and it is the primary driver of most cases today.

The fear that keeps public health officials up at night is urban transmission. If a person infected in the forest returns to a city where the urban mosquito species Aedes aegypti thrives, that mosquito can pick up the virus and spread it person-to-person without any primate involvement. Brazil’s recent outbreaks crept dangerously close to this scenario, with virus circulating in Atlantic Forest fragments near the outskirts of São Paulo and Rio de Janeiro.³ Brazil has not documented an urban yellow fever case since 1942, but the proximity of the 2017-2018 wave to major cities underscored how thin that margin can be.

Non-human primates are not just passive hosts. Mass die-offs among monkeys serve as an early warning system. During the Brazilian outbreak, over 730 laboratory-confirmed yellow fever virus events were recorded in primates in a single monitoring period.³ Howler monkeys are especially vulnerable and suffer the highest mortality, while some other New World primate species can carry the virus with milder illness.⁴ These epizootic die-offs are both a conservation tragedy and a signal that virus activity is intensifying in a region.

What Triggers Outbreaks

The Brazilian epidemic offered a case study in how outbreaks ignite. Researchers built a framework showing that an unusual drought in the state of Minas Gerais concentrated mosquitoes and primates around shrinking water sources, boosting the chances of transmission. Both human and primate cases appeared first in a hot, dry, rural area before the virus spread southeast into more densely populated states.⁵ Confirmed human cases were disproportionately male, working-age, and had recently traveled, pointing to occupational and behavioral exposure in forested areas.⁵

Environmental modeling supports the idea that ecological conditions drive outbreak risk. Key predictors of yellow fever suitability include seasonal humidity changes, the distribution of non-human primates, wind speed (which affects mosquito dispersal in fragmented landscapes), rainfall, and temperature.⁶ Deforestation, expanding agriculture at the forest edge, and climate variability all reshape these variables in ways that can bring infected mosquitoes and unvaccinated people closer together.

What the Disease Does to Your Body

Most people who catch yellow fever have no symptoms at all, or experience a brief illness with fever, muscle aches, and headache that resolves within a few days. The danger lies in the fraction who progress to severe disease. After an initial improvement, these patients enter a “toxic phase” marked by high fever returning, jaundice (the yellowing that gives the disease its name), bleeding, and organ failure.

For years, yellow fever was thought of primarily as a liver disease, but clinical data from the 2016-2019 São Paulo epidemic has shifted that understanding. Researchers now describe severe yellow fever as a complex multiorgan syndrome. The virus damages blood vessel linings and drives down blood pressure, which triggers profound intestinal damage. The gut’s protective barrier breaks down, allowing bacteria to leak into the bloodstream. Because the virus has already crippled the liver’s ability to filter those bacteria, a secondary wave of infection sets in, contributing to the high death rates seen in severe cases.⁷

How deadly is severe yellow fever? A meta-analysis pooling data across studies found a case fatality rate of about 39% among severe cases.⁸ In one hospital series from the Brazilian outbreak, the in-hospital fatality rate was 67%, climbing to 80% among patients with diabetes.⁹ These numbers reflect the worst cases that reached a hospital, not the overall infection fatality rate, but they illustrate how lethal severe yellow fever remains even with modern intensive care. There is no approved antiviral treatment; care is entirely supportive, consisting of fluids, blood products, and organ-support measures.

The Yellow Fever Vaccine

The yellow fever vaccine, based on the live attenuated 17D virus strain developed in the 1930s, is one of the most effective vaccines ever made. A single dose produces protective antibody levels in over 95% of recipients within a couple of weeks. In 2015, the U.S. Advisory Committee on Immunization Practices affirmed that a single primary dose provides long-lasting protection and is adequate for most travelers.¹⁰ The World Health Organization has taken the same position: the International Certificate of Vaccination for yellow fever is now valid for life, and countries cannot require a booster as a condition of entry.¹¹

That said, the “one dose for life” stance is not without debate among immunologists, especially for people living in high-exposure areas versus those visiting briefly as tourists. But for practical purposes, if you got your shot at any point, your certificate does not expire and most countries will accept it indefinitely.

Fractional Doses During Shortages

Global vaccine supply has been a recurring problem. Manufacturing difficulties led to a complete depletion of the only U.S.-licensed yellow fever vaccine in 2017.¹² When outbreaks strike large urban populations, there simply are not enough full doses to go around. The solution has been fractional dosing, giving a fifth of the standard dose to stretch the supply. A trial during an outbreak in Kinshasa, Democratic Republic of the Congo, found that fractional doses of the 17DD vaccine induced seroconversion in 98% of previously seronegative participants at one month, and 97% remained seropositive at one year.¹³ Five-year follow-up data from the same cohort showed that the majority of participants still had detectable antibody titers, supporting the use of fractional doses for sustained outbreak prevention.¹⁴ Fractional doses are not yet accepted on international travel certificates, but they have become a critical tool for emergency campaigns in Africa and South America.

Rare but Serious Vaccine Side Effects

The yellow fever vaccine is considered very safe for most people, but because it is a live virus vaccine, it can occasionally cause the very types of disease it is meant to prevent. Two serious adverse events have specific names: vaccine-associated viscerotropic disease (YEL-AVD), which mimics severe yellow fever with organ failure, and vaccine-associated neurotropic disease (YEL-AND), which involves inflammation of the brain or nervous system. Both are rare. French surveillance data spanning a decade found rates of roughly 0.5 cases of YEL-AND and 0.1 cases of YEL-AVD per 100,000 doses distributed.¹⁵

A review of published YEL-AND case reports identified 53 cases in the literature, predominantly male patients. Most presented with meningoencephalitis, and the majority recovered or improved, though cases presenting as Guillain-Barré syndrome or other demyelinating conditions had a poorer outlook.¹⁶ YEL-AVD, the organ-failure type, is rarer but more dangerous. Risk factors include having had a thymus removal and older age, though the evidence for specific risk groups has been inconsistent across studies.¹⁷

Who Should Think Twice About the Vaccine

Age is the clearest risk modifier. A meta-analysis found that people over 60 face roughly three times the risk of serious adverse events compared to younger adults, and for those over 70, the risk was five times higher. The risk of viscerotropic disease specifically was about six times higher for older adults compared to people under 60.¹⁸ For this reason, vaccination in anyone over 60 who has never been vaccinated should involve a careful individual risk-benefit discussion, and the evidence suggests it may be contraindicated in those over 70, especially for the first dose.

What about people with weakened immune systems? The intuition might be that a live vaccine would be especially dangerous for immunocompromised individuals, but a systematic review and meta-analysis combining six cohort studies found no statistically increased risk of adverse events after yellow fever vaccination in immunocompromised people regardless of the cause of their immunosuppression.¹⁹ That does not mean clinicians hand out the vaccine freely to anyone on immunosuppressive therapy. The evidence is reassuring but limited, and decisions are still made on a case-by-case basis. People with severe immunodeficiency, such as advanced HIV with very low CD4 counts, are generally still advised against receiving the live vaccine.

Why Asia Has Never Had Yellow Fever

One of the enduring puzzles of infectious disease is why yellow fever has never established itself in Asia, despite the presence of Aedes aegypti mosquitoes throughout tropical regions of the continent. Several hypotheses have been floated over the decades, and none on their own fully explains it. One compelling historical argument points to the slave trade. Yellow fever was introduced to the Americas from Africa aboard slave ships carrying infected people and mosquitoes during the 15th and 16th centuries.²⁰ The volume of the trans-Atlantic slave trade was enormous, providing ample opportunity for the virus to cross the ocean and find a foothold. By contrast, the African slave trade to East and Southeast Asia was far smaller, likely insufficient to reach the threshold needed for the virus to become established.²¹

Other proposed factors include cross-protective immunity from dengue virus, which is widespread in Asia and is related to yellow fever, and potential differences in how Asian mosquito populations transmit the virus. A comprehensive review noted that none of the explanations proposed so far is considered fully satisfactory on its own, and the true answer likely involves a combination of historical, ecological, and immunological factors.²² The practical concern today is that this historical absence offers no biological guarantee for the future. With global travel and climate shifts expanding mosquito ranges, the introduction of yellow fever into Asia remains a recognized risk.

Climate Change and the Future of Yellow Fever

Climate projections are not encouraging. A modeling study published in eLife estimated that in even the most optimistic warming scenario, there is a greater than 93% chance that annual yellow fever deaths in Africa will increase by 2050. Under a high-emissions pathway, deaths could rise by about 40% by 2070, though the uncertainty range is wide.²³ Warmer temperatures extend the geographic range and breeding season of mosquito vectors, while changing rainfall patterns create new habitats. The upshot is that regions currently at the margins of yellow fever risk, including highlands in East Africa and parts of South America that rarely see cases, could become transmission zones.

This is not a distant or abstract worry. The Brazilian outbreak showed how ecological disruptions already interact with human behavior to produce explosive case counts. Drought concentrated wildlife and mosquitoes. Deforestation fragmented habitats, pushing primates and mosquitoes into closer contact with people at forest edges. Modeling work confirmed that mosquito and primate ecology together predicted human spillover risk with good accuracy across Brazilian municipalities.²⁴ As climate change accelerates, these patterns will intensify.

The Search for Treatments

There is currently no approved antiviral drug for yellow fever, which is a glaring gap given that the disease kills roughly four in ten people who develop severe illness. Two lines of research are worth watching. The first is a monoclonal antibody called TY014, tested in a phase 1 trial. When given to healthy volunteers who had just received the live yellow fever vaccine (used as a safe stand-in for actual infection), TY014 eliminated detectable virus in all five recipients of the starting dose within 48 hours, compared to persistent viremia in placebo recipients. It also reduced vaccine-associated symptoms.²⁵ The antibody still needs larger trials, but the concept of a rescue therapy for people already infected is promising.

The second approach repurposes sofosbuvir, a drug approved for hepatitis C. During the Brazilian outbreak, 21 hospitalized yellow fever patients received off-label sofosbuvir, and their viral loads showed a steady decline after day seven compared with untreated patients.²⁶ This was a small, nonrandomized study, so the results are suggestive rather than definitive, but they highlight how urgently the field needs randomized trials of antiviral candidates. For now, if you get severe yellow fever, treatment is limited to intensive care support.

Diagnosing Yellow Fever and Why It Gets Tricky

Yellow fever is confirmed through blood tests that detect the virus or antibodies against it, but diagnosis is complicated by the fact that the virus belongs to a large family of related viruses, including dengue, Zika, and West Nile. Antibodies against one flavivirus can cross-react with tests for another, producing misleading results. One study evaluating serological cross-reactivity found that yellow fever sera showed a cross-reactivity rate of about 4% with dengue IgG antibodies on a commercial test kit.²⁷ In regions where dengue and yellow fever both circulate, which includes much of tropical South America and parts of Africa, this overlap can delay accurate diagnosis and complicate surveillance.

Molecular testing that detects the virus’s genetic material is more specific, but it works best during the first few days of illness when virus levels are high. After the first week, antibody-based tests become necessary, and that is where the cross-reactivity problem bites hardest. For travelers returning from endemic areas with fever and jaundice, specialized reference laboratories are often needed to sort out whether yellow fever is the culprit or a lookalike virus is to blame.

Innovative Mosquito Control

Beyond vaccination, researchers are exploring biological approaches to reducing transmission. One promising strategy involves Wolbachia, a naturally occurring bacterium that can be introduced into mosquito populations. When Aedes aegypti mosquitoes carry Wolbachia, their ability to transmit several arboviruses drops dramatically. Laboratory experiments demonstrated that Wolbachia significantly reduced the prevalence of yellow fever virus in mosquito head and thorax tissue, and analyses of mosquito saliva showed a profound reduction in the mosquitoes’ ability to actually transmit the virus.²⁸ Wolbachia-based programs are already being deployed against dengue in several countries. If the approach scales successfully, it could provide an additional layer of protection against yellow fever in urban settings where Aedes aegypti is the primary concern, complementing vaccination rather than replacing it.